Jul 14, 2022

PARP Inhibition in the Management of Prostate Cancer — Where We Are and Where We’re Headed — Faculty Presentation 2: Available Data with, Ongoing Investigation of and Potential Future Role of PARP Inhibitor-Based Combination Strategies — Dr Fred Saad

CME information and select...

Jul 14, 2022

PARP Inhibition in the Management of Prostate Cancer — Where We Are and Where We’re Headed — Faculty Presentation 1: Optimal Integration of PARP Inhibitor Monotherapy into the Management of Metastatic Castration-Resistant Prostate Cancer — Prof Johann de Bono

CME information and select...

Jul 14, 2022

Jun 22, 2022

Featuring perspectives from Drs Andrew Armstrong, Alan Bryce and Alicia Morgans, including the following topics:

• Introduction (0:00)
• Case: A man in his early 70s with DIPSS low- to intermediate-risk post-essential thrombocythemia myelofibrosis (MF) — Warren S Brenner, MD (5:29)
• Case: A woman in her late 60s with...

May 12, 2022

Featuring perspectives from Ms Kathy Burns, Dr Robert Dreicer, Dr Sandy Srinivas and Mr Ronald Stein, including the following topics:

• Introduction (0:00)
• PSA-Only Recurrence (M0 Disease) (10:45)
• Metastatic Hormone-Sensitive Prostate Cancer (35:07)
• Metastatic Castration-Resistant Prostate Cancer (BRCA Wild Type)...